Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
2001 1
2002 1
2003 2
2004 1
2005 1
2007 1
2009 2
2010 1
2012 2
2013 2
2014 3
2015 4
2016 3
2017 3
2018 4
2019 6
2020 5
2021 11
2022 9
2023 8
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.
de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Colombo A, Fyles A, Baron MH, Jürgenliemk-Schulz IM, Kitchener HC, Nijman HW, Wilson G, Brooks S, Carinelli S, Provencher D, Hanzen C, Lutgens LCHW, Smit VTHBM, Singh N, Do V, D'Amico R, Nout RA, Feeney A, Verhoeven-Adema KW, Putter H, Creutzberg CL; PORTEC study group. de Boer SM, et al. Among authors: d amico r. Lancet Oncol. 2018 Mar;19(3):295-309. doi: 10.1016/S1470-2045(18)30079-2. Epub 2018 Feb 12. Lancet Oncol. 2018. PMID: 29449189 Free PMC article. Clinical Trial.
Women with high-risk endometrial cancer should be individually counselled about this combined treatment. Continued follow-up is needed to evaluate long-term survival. FUNDING: Dutch Cancer Society, Cancer Research UK, National Health and Medical Research Council Project Gr …
Women with high-risk endometrial cancer should be individually counselled about this combined treatment. Continued follow-up is needed to ev …
Short-term and long-term effects of tibolone in postmenopausal women.
Formoso G, Perrone E, Maltoni S, Balduzzi S, Wilkinson J, Basevi V, Marata AM, Magrini N, D'Amico R, Bassi C, Maestri E. Formoso G, et al. Among authors: d amico r. Cochrane Database Syst Rev. 2016 Oct 12;10(10):CD008536. doi: 10.1002/14651858.CD008536.pub3. Cochrane Database Syst Rev. 2016. PMID: 27733017 Free PMC article. Review.
BACKGROUND: Tibolone is a synthetic steroid used for the treatment of menopausal symptoms, on the basis of short-term data suggesting its efficacy. We considered the balance between the benefits and risks of tibolone. ...No evidence indicates that tibolone increases the ri …
BACKGROUND: Tibolone is a synthetic steroid used for the treatment of menopausal symptoms, on the basis of short-term data suggesting …
Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study.
Overton ET, Richmond G, Rizzardini G, Thalme A, Girard PM, Wong A, Porteiro N, Swindells S, Reynes J, Noe S, Harrington C, Español CM, Acuipil C, Aksar A, Wang Y, Ford SL, Crauwels H, van Eygen V, Van Solingen-Ristea R, Latham CL, Thiagarajah S, D'Amico R, Smith KY, Vandermeulen K, Spreen WR. Overton ET, et al. Among authors: d amico r. Clin Infect Dis. 2023 May 3;76(9):1646-1654. doi: 10.1093/cid/ciad020. Clin Infect Dis. 2023. PMID: 36660819 Free PMC article. Clinical Trial.
CONCLUSIONS: These data demonstrate virologic suppression durability with CAB+RPV LA Q8W or Q4W for 3 years and confirm long-term efficacy, safety, and tolerability of CAB+RPV LA as a complete regimen to maintain HIV-1 virologic suppression....
CONCLUSIONS: These data demonstrate virologic suppression durability with CAB+RPV LA Q8W or Q4W for 3 years and confirm long-term eff …
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial.
de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, D'Amico R, Fyles A, Baron MH, Jürgenliemk-Schulz IM, Kitchener HC, Nijman HW, Wilson G, Brooks S, Gribaudo S, Provencher D, Hanzen C, Kruitwagen RF, Smit VTHBM, Singh N, Do V, Lissoni A, Nout RA, Feeney A, Verhoeven-Adema KW, Putter H, Creutzberg CL; PORTEC Study Group. de Boer SM, et al. Among authors: d amico r. Lancet Oncol. 2019 Sep;20(9):1273-1285. doi: 10.1016/S1470-2045(19)30395-X. Epub 2019 Jul 22. Lancet Oncol. 2019. PMID: 31345626 Free PMC article. Clinical Trial.
This treatment schedule should be discussed and recommended, especially for women with stage III or serous cancers, or both, as part of shared decision making between doctors and patients. Follow-up is ongoing to evaluate long-term survival. FUNDING: Dutch Cancer Society, …
This treatment schedule should be discussed and recommended, especially for women with stage III or serous cancers, or both, as part of shar …
Direct Wave Intraoperative Neuromonitoring for Spinal Tumor Resection: A Focused Review.
Olmsted ZT, Ryu B, Phayal G, Green R, Lo SL, Sciubba DM, Silverstein JW, D'Amico RS. Olmsted ZT, et al. Among authors: d amico rs. World Neurosurg X. 2022 Sep 15;17:100139. doi: 10.1016/j.wnsx.2022.100139. eCollection 2023 Jan. World Neurosurg X. 2022. PMID: 36217537 Free PMC article. Review.
Together with motor-evoked potentials, D-waves can help to guide the extent of tumor resection and provide intraoperative warning signs and alarm criteria to direct the surgical strategy. D-waves can also serve as prognostic biomarkers for long-term recovery of postoperati …
Together with motor-evoked potentials, D-waves can help to guide the extent of tumor resection and provide intraoperative warning signs and …
Convection-enhanced drug delivery for glioblastoma: a review.
D'Amico RS, Aghi MK, Vogelbaum MA, Bruce JN. D'Amico RS, et al. J Neurooncol. 2021 Feb;151(3):415-427. doi: 10.1007/s11060-020-03408-9. Epub 2021 Feb 21. J Neurooncol. 2021. PMID: 33611708 Free PMC article. Review.
However, the heterogeneity of both, the surgical procedure and the mechanisms of action of the agents studied-combined with the additional costs of performing a trial evaluating CED-has limited the field's ability to adequately assess the durability of any potential anti-tumor re …
However, the heterogeneity of both, the surgical procedure and the mechanisms of action of the agents studied-combined with the additional c …
Worse global intellectual and worse neuropsychological functioning in preterm-born children at preschool age: a meta-analysis.
Arpi E, D'Amico R, Lucaccioni L, Bedetti L, Berardi A, Ferrari F. Arpi E, et al. Among authors: d amico r. Acta Paediatr. 2019 Sep;108(9):1567-1579. doi: 10.1111/apa.14836. Epub 2019 Jul 25. Acta Paediatr. 2019. PMID: 31069843 Review.

This review aimed to evaluate the extent to which total intelligence quotient (IQ) and neuropsychological functions at ages three to five years differ between children born at <32 weeks gestational age or < 1500 g birth weight and children born at term. The se

…
This review aimed to evaluate the extent to which total intelligence quotient (IQ) and neuropsychological functions at ages three to five ye …
Neurosurgical oncology: advances in operative technologies and adjuncts.
D'Amico RS, Kennedy BC, Bruce JN. D'Amico RS, et al. J Neurooncol. 2014 Sep;119(3):451-63. doi: 10.1007/s11060-014-1493-3. Epub 2014 Jun 27. J Neurooncol. 2014. PMID: 24969924 Review.
Technologies such as cortical and subcortical stimulation mapping, intraoperative magnetic resonance imaging, functional neuronavigation, navigable intraoperative ultrasound, neuroendoscopy, and fluorescence-guided resection have been developed to augment the identification of tu …
Technologies such as cortical and subcortical stimulation mapping, intraoperative magnetic resonance imaging, functional neuronavigation, na …
Cyclophosphamide for multiple sclerosis.
La Mantia L, Milanese C, Mascoli N, D'Amico R, Weinstock-Guttman B. La Mantia L, et al. Among authors: d amico r. Cochrane Database Syst Rev. 2007 Jan 24;2007(1):CD002819. doi: 10.1002/14651858.CD002819.pub2. Cochrane Database Syst Rev. 2007. PMID: 17253481 Free PMC article. Review.
Intensive immunosuppression with CFX (alone or associated with ACTH or prednisone) in patients with progressive MS compared to placebo or no treatment (152 participants) did not prevent the long-term (12, 18, 24 months) clinical disability progression as defined as evoluti …
Intensive immunosuppression with CFX (alone or associated with ACTH or prednisone) in patients with progressive MS compared to placebo or no …
Cyclophosphamide for multiple sclerosis.
La Mantia L, Milanese C, Mascoli N, Incorvaia B, D'Amico R, Weinstock-Guttman B. La Mantia L, et al. Among authors: d amico r. Cochrane Database Syst Rev. 2002;(4):CD002819. doi: 10.1002/14651858.CD002819. Cochrane Database Syst Rev. 2002. PMID: 12519578 Updated. Review.
Intensive immunosuppression with CFX (alone or associated with ACTH or prednisone) in patients with progressive MS compared to placebo or no-treatment (152 participants) did not prevent the long -term (12-18-24 months) risk to evolution to a next step of EDSS. ...
Intensive immunosuppression with CFX (alone or associated with ACTH or prednisone) in patients with progressive MS compared to placebo or no …
61 results